Reuter Stefan, Manfras Burkhard, Merkle Marion, Härter Georg, Kern Peter
Section of Infectious Diseases and Clinical Immunology, University Hospital of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany.
Antimicrob Agents Chemother. 2006 Sep;50(9):2966-70. doi: 10.1128/AAC.00476-06.
Albendazole (ABZ) and mebendazole are the only drugs licensed for treatment of human alveolar echinococcosis. In order to augment the armamentarium against this deadly disease, we tested a series of drugs for their efficacy against Echinococcus multilocularis larvae. E. multilocularis larvae grown intraperitoneally in Mongolian gerbils were transferred into tissue culture. Vesicles budded from the tissue blocks and after 6 weeks, drugs were added, and the effect on the vesicles was observed. We tested the following drugs at various concentrations: ABZ, artemether, caspofungin, itraconazole (ITZ), ivermectin, methiazole (MTZ), miltefosine, nitazoxanide (NTZ), rifampin, and trimethoprim-sulfamethoxazole. ABZ, ITZ, MTZ, and NTZ effectively destroyed parasite vesicles in this in vitro culture system. At high NTZ doses of 10 microg/ml, disintegration of all vesicles was observed after 7 days and was significantly more rapid than with ABZ at equal concentrations (21 days). After drug discontinuation, regrowth of vesicles occurred between 7 and 14 days for all four drugs, indicating a parasitostatic effect. Combination treatment with NTZ-ABZ at concentrations between 1 and 10 microg/ml for either 3 weeks, 3 months, or 6 months yielded no vesicle regrowth during 8 months after drug discontinuation. The treated larval tissue was injected intraperitoneally into gerbils, and no regrowth of larval tissue was observed, suggesting a parasitocidal effect after combined treatment. ITZ, MTZ, and NTZ are potent inhibitors of larval growth, although they proved to be parasitostatic only. The combination of NTZ plus ABZ was parasitocidal in vitro. Animal experiments are warranted for studies of dose, toxicity, and drug interactions.
阿苯达唑(ABZ)和甲苯达唑是仅有的被批准用于治疗人类肺泡型棘球蚴病的药物。为了增加对抗这种致命疾病的手段,我们测试了一系列药物对多房棘球绦虫幼虫的疗效。将在蒙古沙鼠腹腔内生长的多房棘球绦虫幼虫转移到组织培养中。从组织块上长出囊泡,6周后加入药物,并观察对囊泡的影响。我们在不同浓度下测试了以下药物:阿苯达唑、蒿甲醚、卡泊芬净、伊曲康唑(ITZ)、伊维菌素、甲噻唑(MTZ)、米替福新、硝唑尼特(NTZ)、利福平以及甲氧苄啶 - 磺胺甲恶唑。在这个体外培养系统中,阿苯达唑、伊曲康唑、甲噻唑和硝唑尼特有效地破坏了寄生虫囊泡。在高剂量硝唑尼特(10微克/毫升)时,7天后观察到所有囊泡解体,且比相同浓度(21天)的阿苯达唑解体速度明显更快。停药后,所有四种药物在7至14天之间囊泡出现再生,表明具有寄生虫生长抑制作用。硝唑尼特 - 阿苯达唑以1至10微克/毫升的浓度联合治疗3周、3个月或6个月,停药后8个月内未出现囊泡再生。将处理后的幼虫组织腹腔注射到沙鼠体内,未观察到幼虫组织再生,表明联合治疗后具有杀寄生虫作用。伊曲康唑、甲噻唑和硝唑尼特是幼虫生长的有效抑制剂,尽管它们仅被证明具有寄生虫生长抑制作用。硝唑尼特加阿苯达唑的组合在体外具有杀寄生虫作用。有必要进行动物实验以研究剂量、毒性和药物相互作用。